Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development

Breast Cancer Research

Volumn 11, Issue 5, 2009, Pages

  Whyte, Jacqueline ^a   Bergin, Orla ^b   Bianchi, Alessandro ^b   McNally, Sara ^b   Martin, Finian ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BCL 2 MODIFYING FACTOR; BH3 PROTEIN; BIM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR 30; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CELL; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL POLARITY; CELL PROLIFERATION; CELL SURVIVAL; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE MUTATION; HUMAN; MAMMARY GLAND; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; DISEASE COURSE; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; PATHOLOGY; UDDER;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3;

EID: 77449145601     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2361     Document Type: Review

References (182)

1. Krishna M, Narang H. The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci 2008, 65:3525-3544. 10.1007/s00018-008-8170-7, 18668205.
2. Wang X, Tournier C. Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 2006, 18:753-760. 10.1016/j.cellsig.2005.11.003, 16376520.
3. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002, 80:239-256. 10.1016/S0960-0760(01)00189-3, 11897507.
4. May LT, Hill SJ. ERK phosphorylation: spatial and temporal regulation by G protein-coupled receptors. Int J Biochem Cell Biol 2008, 40:2013-2017. 10.1016/j.biocel.2008.04.001, 18502166.
5. Eblen ST, Slack-Davis JK, Tarcsafalvi A, Parsons JT, Weber MJ, Catling AD. Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol Cell Biol 2004, 24:2308-2317. 355870, 14993270, 10.1128/MCB.24.6.2308-2317.2004.
6. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 2008, 40:2707-2719. 10.1016/j.biocel.2008.04.009, 18562239.
7. Fata JE, Mori H, Ewald AJ, Zhang H, Yao E, Werb Z, Bissell MJ. The MAPK(ERK-1,2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in morphogenesis of mouse mammary epithelium. Dev Biol 2007, 306:193-207. 10.1016/j.ydbio.2007.03.013, 17448457, 2763137.
8. Nguyen DH, Webb DJ, Catling AD, Song Q, Dhakephalkar A, Weber MJ, Ravichandran KS, Gonias SL. Urokinase-type plasminogen activator stimulates the Ras/Extracellular signal-regulated kinase (ERK) signalling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem 2000, 275:19382-19388. 10.1074/jbc.M909575199, 10777511.
9. Song RX, Zhang Z, Chen Y, Bao Y, Santen RJ. Estrogen signalling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007, 148:4091-4101. 2727866, 17525128, 10.1210/en.2007-0240.
10. Filardo EJ, Quinn JA, Bland KI, Frackelton AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000, 14:1649-1660. 10.1210/me.14.10.1649, 11043579.
11. Liu ZX, Yu CF, Nickel C, Thomas S, Cantley LG. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J Biol Chem 2002, 277:10452-10458. 10.1074/jbc.M107551200, 11784715.
12. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, van Bergen en Henegouwen P. The epidermal growth factor. Cell Biol Int 1995, 19:413-430. 10.1006/cbir.1995.1086, 7640657.
13. Schlessinger J. Cell signalling by receptor tyrosine kinases. Cell 2000, 103:211-225. 10.1016/S0092-8674(00)00114-8, 11057895.
14. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153-183. 10.1210/er.22.2.153, 11294822.
15. Pagès G, Milanini J, Richard DE, Berra E, Gothié E, Viñals F, Pouysségur J. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000, 902:187-200.
16. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signalling from autocrine stimulation. J Cell Sci 2007, 120:3688-3699. 10.1242/jcs.010488, 17895366.
17. Price DJ, Avraham S, Feuerstein J, Fu Y, Avraham HK. The invasive phenotype in HMT-3522 cells requires increased EGF receptor signalling through both PI 3-kinase and ERK 1,2 pathways. Cell Commun Adhes 2002, 9:87-102. 10.1080/15419060214147, 12487410.
18. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehren-bacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
19. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signalling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 2003, 22:237-252.
20. Wang C, Thor AD, Moore DH, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signalling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 1998, 4:567-576.
21. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 2006, 5:31. 1560159, 16899113, 10.1186/1476-4598-5-31.
22. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279. 10.1016/j.advenzreg.2006.01.004, 16854453.
23. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000, 89:384-388. 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R, 10956414.
24. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JM, Cooke TG. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009, 15:1487-1495. 10.1158/1078-0432.CCR-07-4967, 19228750.
25. Pinkas J, Leder P. MEK1 signalling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. Cancer Res 2002, 62:4781-4790.
26. Bergqvist J, Elmberger G, Ohd J, Linderholm B, Bjohle J, Hellborg H, Nordgren H, Borg AL, Skoog L, Bergh J. Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer 2006, 42:1104-1112. 10.1016/j.ejca.2006.01.028, 16603346.
27. Svensson S, Jirström K, Rydén L, Roos G, Emdin S, Ostrowski MC, Landberg G. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005, 24:4370-4379. 10.1038/sj.onc.1208626, 15806151.
28. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, Löning T. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005, 92:2206-2215. 2361826, 15928662, 10.1038/sj.bjc.6602655.
29. Blatchford DR, Quarrie LH, Tonner E, McCarthy C, Flint DJ, Wilde CJ. Influence of microenvironment on mammary epithelial cell survival in primary culture. J Cell Physiol 1999, 181:304-311. 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5, 10497309.
30. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005, 5:675-688. 10.1038/nrc1695, 16148884.
31. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, Bissell MJ. Phenotypic reversion or death of cancer cells by altering signalling pathways in three-dimensional contexts. J Natl Cancer Inst 2002, 94:1494-1503.
32. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468. 10.1038/onc.2008.394, 18978815.
33. Brummer T, Schramek D, Hayes VM, Bennett HL, Caldon CE, Musgrove EA, Daly RJ. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 2006, 281:626-637. 10.1074/jbc.M509567200, 16253990.
34. Xian W, Schwertfeger KL, Rosen JM. Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition. Mol Endocrinol 2007, 21:987-1000. 10.1210/me.2006-0518, 17284663.
35. Seton-Rogers SE, Lu Y, Hines LM, Koundinya M, LaBaer J, Muthuswamy SK, Brugge JS. Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci USA 2004, 101:1257-1262. 337040, 14739340, 10.1073/pnas.0308090100.
36. Nolan ME, Aranda V, Lee S, Lakshmi B, Basu S, Allred DC, Muthuswamy SK. The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer. Cancer Res 2008, 68:8201-8209. 10.1158/0008-5472.CAN-07-6567, 18922891.
37. Reginato MJ, Mills KR, Becker EB, Lynch DK, Bonni A, Muthuswamy SK, Brugge JS. Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol 2005, 25:4591-4601. 1140636, 15899862, 10.1128/MCB.25.11.4591-4601.2005.
38. Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES, Veiby OP, Brugge JS. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci USA 2007, 104:3787-3792. 1820662, 17360431, 10.1073/pnas.0700115104.
39. Mailleux AA, Overholtzer M, Schmelzle T, Bouillet P, Strasser A, Brugge JS. BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell 2007, 12:221-234. 2698712, 17276340, 10.1016/j.devcel.2006.12.003.
40. Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signalling pathways. J Cell Biol 2002, 156:299-313. 2199233, 11790801, 10.1083/jcb.200109037.
41. Smith AP, Verrecchia A, Fagà G, Doni M, Perna D, Martinato F, Guccione E, Amati B. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 2009, 28:422-430. 10.1038/onc.2008.395, 18978814.
42. Katoh M, Katoh M. Crosstalk of WNT and FGF signalling pathways at GSK3beta to regulate beta-catenin and SNAIL signalling cascades. Cancer Biol Ther 2006, 5:1059-1064.
43. Horn G, Gaziel A, Wreschner DH, Smorodinsky NI, Ehrlich M. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1. Exp Cell Res 2009, 315:1490-1504. 10.1016/j.yexcr.2009.02.011, 19245809.
44. Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ, Brachtel E, Ramaswamy S, Maheswaran S, Haber DA. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev 2009, 23:1737-1742. 2720264, 19651985, 10.1101/gad.1809309.
45. Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol 2007, 21:2907-2918. 2668600, 17761946, 10.1210/me.2007-0293.
46. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM, Derynck R. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 2007, 26:3957-3967. 1994119, 17673906, 10.1038/sj.emboj.7601818.
47. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, Saito H. Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J 2002, 21:6473-6482. 136947, 12456654, 10.1093/emboj/cdf643.
48. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signalling in MCF10A human breast epithelial cells. Int J Oncol 2004, 25:1375-1382.
49. Ingman WV, Robertson SA. Mammary gland development in transforming growth factor beta1 null mutant mice: systemic and epithelial effects. Biol Reprod 2008, 79:711-717. 10.1095/biolreprod.107.067272, 18614704.
50. Monks J. TGFbeta as a potential mediator of progesterone action in the mammary gland of pregnancy. J Mammary Gland Biol Neoplasia 2007, 12:249-257. 10.1007/s10911-007-9056-2, 18027075.
51. Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA, Moses HL. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol 2003, 163:1539-1549. 1868288, 14507660.
52. Nelson CM, Vanduijn MM, Inman JL, Fletcher DA, Bissell MJ. Tissue geometry determines sites of mammary branching morphogenesis in organotypic cultures. Science 2006, 314:298-300. 10.1126/science.1131000, 17038622.
53. McCawley LJ, Li S, Wattenberg EV, Hudson LG. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 1999, 274:4347-4353. 10.1074/jbc.274.7.4347, 9933637.
54. Kim MS, Lee EJ, Kim HR, Moon A. p38 kinase is a key signalling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 2003, 63:5454-5461.
55. Kim ES, Kim MS, Moon A. Transforming growth factor (TGF)-beta in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine 2005, 29:84-91. 10.1016/j.cyto.2004.10.001, 15598443.
56. Gandhari M, Arens N, Majety M, Dorn-Beineke A, Hildenbrand R. Urokinase-type plasminogen activator induces proliferation in breast cancer cells. Int J Oncol 2006, 28:1463-1470.
57. Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001, 114:3387-3396.
58. Seddighzadeh M, Zhou JN, Kronenwett U, Shoshan MC, Auer G, Sten-Linder M, Wiman B, Linder S. ERK signalling in metastatic human MDA-MB-231 breast carcinoma cells is adapted to obtain high urokinase expression and rapid cell proliferation. Clin Exp Metastasis 1999, 17:649-654. 10.1023/A:1006741228402, 10919709.
59. Green KA, Lund LR. ECM degrading proteases and tissue remodelling in the mammary gland. Bioessays 2005, 27:894-903. 10.1002/bies.20281, 16108064.
60. Zhao J, Pestell R, Guan JL. Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. Mol Biol Cell 2001, 12:4066-4077. 60776, 11739801.
61. Kritikou EA, Sharkey A, Abell K, Came PJ, Anderson E, Clarkson RW, Watson CJ. A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 2003, 130:3459-3468. 10.1242/dev.00578, 12810593.
62. Viala E, Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann N Y Acad Sci 2004, 1030:208-218. 10.1196/annals.1329.027, 15659800.
63. Hazan RB, Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998, 273:9078-9084. 10.1074/jbc.273.15.9078, 9535896.
64. Li Q, Mattingly RR. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. Neoplasia 2008, 10:1444-1458. 2586695, 19048123.
65. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000, 148:779-790. 2169367, 10684258, 10.1083/jcb.148.4.779.
66. Hulit J, Suyama K, Chung S, Keren R, Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen K, Hazan RB. N-cad-herin signalling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 2007, 67:3106-3116. 10.1158/0008-5472.CAN-06-3401, 17409417.
67. Dow LE, Elsum IA, King CL, Kinross KM, Richardson HE, Humbert PO. Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling. Oncogene 2008, 27:5988-6001. 10.1038/onc.2008.219, 18641685.
68. Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: Intracellular signalling and the actin cytoskeleton. Cancer Lett 2009, 284:122-130. 10.1016/j.canlet.2009.02.034, 19303207.
69. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004, 117:4619-4628. 10.1242/jcs.01481, 15371522.
70. Vadlamudi RK, Adam L, Nguyen D, Santos M, Kumar R. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. J Cell Physiol 2002, 190:189-199. 10.1002/jcp.10054, 11807823.
71. Lunn JA, Jacamo R, Rozengurt E. Preferential phosphorylation of focal adhesion kinase tyrosine 861 is critical for mediating an anti-apoptotic response to hyperosmotic stress. J Biol Chem 2007, 282:10370-10379. 10.1074/jbc.M607780200, 17289681.
72. Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, Alaoui-Jamali MA. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol 2008, 173:1540-1550. 2570143, 18832579, 10.2353/ajpath.2008.080292.
73. Nagy T, Wei H, Shen TL, Peng X, Liang CC, Gan B, Guan JL. Mammary epithelial-specific deletion of the focal adhesion kinase gene leads to severe lobulo-alveolar hypoplasia and secretory immaturity of the murine mammary gland. J Biol Chem 2007, 282:31766-31776. 10.1074/jbc.M705403200, 17716968.
74. Huang S, Ingber DE. Cell tension, matrix mechanics, and cancer development. Cancer Cell 2005, 8:175-176. 10.1016/j.ccr.2005.08.009, 16169461.
75. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998, 95:14821-14826. 24533, 9843973, 10.1073/pnas.95.25.14821.
76. Prescott JD, Koto KS, Singh M, Gutierrez-Hartmann A. The ETS transcription factor ESE-1 transforms MCF-12A human mammary epithelial cells via a novel cytoplasmic mechanism. Mol Cell Biol 2004, 24:5548-5564. 419891, 15169914, 10.1128/MCB.24.12.5548-5564.2004.
77. Gilles C, Polette M, Birembaut P, Brünner N, Thompson EW. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 1997, 15:519-526. 10.1023/A:1018427027270, 9247254.
78. Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S, Fujinaga K. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated uroki-nase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998, 77:128-137. 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9, 9639404.
79. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324:1670-1673. 10.1126/science.1171837, 19556499.
80. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 153034, 12629218, 10.1073/pnas.0530291100.
81. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888. 2492808, 18682804, 10.1371/journal.pone.0002888.
82. Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res 2007, 67:8671-8681. 10.1158/0008-5472.CAN-07-1486, 17875707.
83. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007, 256:1-24. 2533271, 17475399, 10.1016/j.canlet.2007.03.016.
84. Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston SR, Jones HE, Wakeling AE, Duncan R, Nicholson RI. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer 2005, 12(Suppl 1):S1-7. 10.1677/erc.1.01054, 16113086.
85. Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI. The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol 2009, 87:1-11. 10.1016/j.yexmp.2009.05.001, 19450579.
86. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284. 2696318, 17126425, 10.1016/j.bbamcr.2006.10.001.
87. Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer 2008, 8:129. 2386479, 18454859, 10.1186/1471-2407-8-129.
88. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001, 3:785-792. 10.1038/ncb0901-785, 11533657.
89. Aranda V, Haire T, Nolan ME, Calarco JP, Rosenberg AZ, Fawcett JP, Pawson T, Muthuswamy SK. Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control. Nat Cell Biol 2006, 8:1235-1245. 10.1038/ncb1485, 17060907.
90. Kim IY, Yong HY, Kang KW, Moon A. Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett 2009, 275:227-233. 10.1016/j.canlet.2008.10.013, 19022565.
91. Rodland KD, Bollinger N, Ippolito D, Opresko LK, Coffey RJ, Zangar R, Wiley HS. Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells. J Biol Chem 2008, 283:31477-31487. 10.1074/jbc.M800456200, 18782770.
92. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996, 379:557-560. 10.1038/379557a0, 8596637.
93. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
94. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007, 27:466-480. 1800800, 17074804, 10.1128/MCB.01539-06.
95. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7:389-397. 10.1038/nrc2127, 17446858.
96. Marcotte R, Muller WJ. Signal transduction in transgenic mouse models of human breast cancer--implications for human breast cancer. J Mammary Gland Biol Neoplasia 2008, 13:323-335. 10.1007/s10911-008-9087-3, 18651209.
97. Julien SG, Dubé N, Read M, Penney J, Paquet M, Han Y, Kennedy BP, Muller WJ, Tremblay ML. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet 2007, 39:338-346. 10.1038/ng1963, 17259984.
98. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007, 26:2502-2506. 10.1038/sj.onc.1210032, 17016428.
99. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008, 10:138-148. 2376808, 18204439, 10.1038/ncb1676.
100. Vaught D, Chen J, Brantley-Sieders DM. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell 2009, 20:2572-2581. 2682598, 19321667, 10.1091/mbc.E08-04-0378.
101. Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signalling. J Clin Invest 2008, 118:64-78. 2129239, 18079969, 10.1172/JCI33154.
102. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006, 12:7242-7251. 10.1158/1078-0432.CCR-06-0646, 17189395.
103. Arany I, Megyesi JK, Nelkin BD, Safirstein RL. STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 2006, 70:669-674. 10.1038/sj.ki.5001604, 16788692.
104. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510. 10.1126/science.277.5331.1508, 9278514.
105. Green S, Chambon P. Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor. Nature 1987, 325:75-78. 10.1038/325075a0, 3025750.
106. Nilsson S, Gustafsson JA. Estrogen receptor transcription and transactivation: Basic aspects of estrogen action. Breast Cancer Res 2000, 2:360-366. 138658, 11250729, 10.1186/bcr81.
107. Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu YL, Troup S, Tomes L, Watson PH. Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo. J Steroid Biochem Mol Biol 2006, 102:139-146. 10.1016/j.jsbmb.2006.09.021, 17092701.
108. Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 2005, 7:R753-764. 1242143, 16168121, 10.1186/bcr1285.
109. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006, 20:3120-3132. 10.1210/me.2006-0068, 16945990.
110. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006, 96:131-146. 10.1007/s10549-005-9070-2, 16261397.
111. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S, Coombes RC, Ali S. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 2006, 13:851-861. 10.1677/erc.1.01123, 16954434.
112. Filardo EJ, Quinn JA, Frackelton AR, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signalling axis. Mol Endocrinol 2002, 16:70-84. 10.1210/me.16.1.70, 11773440.
113. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J 2000, 19:4688-4700. 302047, 10970861, 10.1093/emboj/19.17.4688.
114. Figtree GA, McDonald D, Watkins H, Channon KM. Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 2003, 107:120-126. 10.1161/01.CIR.0000043805.11780.F5, 12515753.
115. Denger S, Reid G, Kos M, Flouriot G, Parsch D, Brand H, Korach KS, Sonntag-Buck V, Gannon F. ERalpha gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol 2001, 15:2064-2077. 10.1210/me.15.12.2064, 11731609.
116. Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 2003, 100:4807-4812. 153637, 12682286, 10.1073/pnas.0831079100.
117. Rosen EM, Fan S, Ma Y, Levin ER. Role of plasma membrane ER protein in breast cancer. Breast Cancer Online 2006, 9:1-5. 10.1017/S1470903105003366.
118. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC, Bender JR. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 2003, 278:2118-2123. 10.1074/jbc.M210828200, 12431978.
119. Henderson IC, Piccart-Gebhart MJ. The evolving role of aro-matase inhibitors in adjuvant breast cancer therapy. Clin Breast Cancer 2005, 6:206-215. 10.3816/CBC.2005.n.022, 16137430.
120. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001, 7:4436s-4442s. discussion 4411s-4412s..
121. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044. 10.1210/en.2002-220620, 12586780.
122. Webb CP, Van Aelst L, Wigler MH, Woude GF. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 1998, 95:8773-8778. 21152, 9671754, 10.1073/pnas.95.15.8773.
123. Ciarloni L, Mallepell S, Brisken C. Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci USA 2007, 104:5455-5460. 1838509, 17369357, 10.1073/pnas.0611647104.
124. Wiesen JF, Young P, Werb Z, Cunha GR. Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 1999, 126:335-344.
125. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 2002, 99:14783-14788. 137496, 12415108, 10.1073/pnas.192569699.
126. Nguyen TH, Mustafa FB, Pervaiz S, Ng FS, Lim LH. ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells. Int J Oncol 2008, 33:81-92.
127. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extra-cellular-signal-regulated protein kinases and p38 kinase. Cancer Res 2001, 61:1604-1610.
128. Yu W, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. Cancer Res 2003, 63:2483-2491.
129. Li Z, Li J, Mo B, Hu C, Liu H, Qi H, Wang X, Xu J. Genistein induces cell apoptosis in MDA-MB-231 breast cancer cells via the mitogen-activated protein kinase pathway. Toxicol In Vitro 2008, 22:1749-1753. 10.1016/j.tiv.2008.08.001, 18761399.
130. Jo EH, Lee SJ, Ahn NS, Park JS, Hwang JW, Kim SH, Aruoma OI, Lee YS, Kang KS. Induction of apoptosis in MCF-7 and MDA-MB-231 breast cancer cells by Oligonol is mediated by Bcl-2 family regulation and MEK/ERK signalling. Eur J Cancer Prev 2007, 16:342-347. 10.1097/01.cej.0000236247.86360.db, 17554207.
131. Kim BW, Lee ER, Min HM, Jeong HS, Ahn JY, Kim JH, Choi HY, Choi H, Kim EY, Park SP, Cho SG. Sustained ERK activation is involved in the kaempferol-induced apoptosis of breast cancer cells and is more evident under 3-D culture condition. Cancer Biol Ther 2008, 7:1080-1089. 10.1158/1535-7163.MCT-07-0526, 18443432.
132. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF, Cook SJ. Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 2003, 22:1281-1293. 10.1038/sj.onc.1206261, 12618753.
133. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signalling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 2003, 278:18811-18816. 10.1074/jbc.M301010200, 12646560.
134. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 2004, 101:15313-15317. 524459, 15486085, 10.1073/pnas.0406837101.
135. Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ 2009, 16:664-673. 10.1038/cdd.2008.190, 19136936.
136. Phelps M, Phillips A, Darley M, Blaydes JP. MEK-ERK signalling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem 2005, 280:16651-16658. 10.1074/jbc.M412334200, 15723837.
137. Wu GS. The functional interactions between the p53 and MAPK signalling pathways. Cancer Biol Ther 2004, 3:156-161.
138. Ostrakhovitch EA, Cherian MG. Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis. J Cell Biochem 2005, 95:1120-1134. 10.1002/jcb.20484, 15880691.
139. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 1999, 13:2604-2616. 317074, 10521404, 10.1101/gad.13.19.2604.
140. Zhao L, Melenhorst JJ, Hennighausen L. Loss of interleukin 6 results in delayed mammary gland involution: a possible role for mitogen-activated protein kinase and not signal transducer and activator of transcription. Mol Endocrinol 2002, 16:2902-2912. 10.1210/me.2001-0330, 12456808.
141. Hui L, Bakiri L, Stepniak E, Wagner EF. p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle 2007, 6:2429-2433.
142. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270:7420-7426. 10.1074/jbc.270.13.7420, 7535770.
143. Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci 2009, 5:44-51. 2610339, 19159010.
144. Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002, 295:1291-1294. 10.1126/science.1067289, 11847341.
145. Morooka H, Bonventre JV, Pombo CM, Kyriakis JM, Force T. Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. J Biol Chem 1995, 270:30084-30092. 10.1074/jbc.270.50.30084, 8530413.
146. Zhao M, New L, Kravchenko VV, Kato Y, Gram H, di Padova F, Olson EN, Ulevitch RJ, Han J. Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol 1999, 19:21-30. 83862, 9858528.
147. Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem 2000, 275:12266-12272. 10.1074/jbc.275.16.12266, 10766865.
148. Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK, Han J, Huang S. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J Biol Chem 2002, 277:48379-48385. 10.1074/jbc.M209542200, 12377770.
149. Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 2007, 67:3752-3758. 10.1158/0008-5472.CAN-06-3851, 17440088.
150. Sossey-Alaoui K, Ranalli TA, Li X, Bakin AV, Cowell JK. WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Exp Cell Res 2005, 308:135-145. 10.1016/j.yexcr.2005.04.011, 15907837.
151. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005, 23:2469-2476. 10.1200/JCO.2005.01.172, 15753463.
152. Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 2002, 22:5835-5845. 133965, 12138194, 10.1128/MCB.22.16.5835-5845.2002.
153. Davis RJ. Signal transduction by the c-Jun N-terminal kinase. Biochem Soc Symp 1999, 64:1-12.
154. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001, 20:2401-2412. 10.1038/sj.onc.1204389, 11402336.
155. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Berg CL. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 2004, 23:596-604. 10.1038/sj.onc.1207147, 14724588.
156. Monno S, Newman MV, Cook M, Lowe WL. Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells. Endocrinology 2000, 141:544-550. 10.1210/en.141.2.544, 10650934.
157. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 1999, 5:251-256.
158. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000, 92:1926-1934. 10.1093/jnci/92.23.1926, 11106684.
159. Buse P, Woo PL, Alexander DB, Reza A, Firestone GL. Glucocorticoid-induced functional polarity of growth factor responsiveness regulates tight junction dynamics in transformed mammary epithelial tumor cells. J Biol Chem 1995, 270:28223-28227. 10.1074/jbc.270.47.28223, 7499317.
160. Murtagh J, McArdle E, Gilligan E, Thornton L, Furlong F, Martin F. Organization of mammary epithelial cells into 3D acinar structures requires glucocorticoid and JNK signalling. J Cell Biol 2004, 166:133-143. 2172147, 15226308, 10.1083/jcb.200403020.
161. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, Allred C, Muthuswamy SK. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 2008, 135:865-878. 10.1016/j.cell.2008.09.045, 19041750.
162. Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun 1995, 213:715-724. 10.1006/bbrc.1995.2189, 7646528.
163. Yan C, Luo H, Lee JD, Abe J, Berk BC. Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. J Biol Chem 2001, 276:10870-10878. 10.1074/jbc.M009286200, 11139578.
164. English JM, Vanderbilt CA, Xu S, Marcus S, Cobb MH. Isolation of MEK5 and differential expression of alternatively spliced forms. J Biol Chem 1995, 270:28897-28902. 10.1074/jbc.270.48.28897, 7499418.
165. Wang X, Merritt AJ, Seyfried J, Guo C, Papadakis ES, Finegan KG, Kayahara M, Dixon J, Boot-Handford RP, Cartwright EJ, Mayer U, Tournier C. Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol 2005, 25:336-345. 538774, 15601854, 10.1128/MCB.25.1.336-345.2005.
166. Hayashi M, Kim SW, Imanaka-Yoshida K, Yoshida T, Abel ED, Eliceiri B, Yang Y, Ulevitch RJ, Lee JD. Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 2004, 113:1138-1148. 385403, 15085193.
167. Pi X, Yan C, Berk BC. Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ Res 2004, 94:362-369. 10.1161/01.RES.0000112406.27800.6F, 14670836.
168. Suhara T, Kim HS, Kirshenbaum LA, Walsh K. Suppression of Akt signalling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol 2002, 22:680-691. 139747, 11756562, 10.1128/MCB.22.2.680-691.2002.
169. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998, 395:713-716. 10.1038/27234, 9790194.
170. Sawhney RS, Liu W, Brattain MG. A novel role of ERK5 in integrin-mediated cell adhesion and motility in cancer cells via Fak signalling. J Cell Physiol 2009, 219:152-161. 10.1002/jcp.21662, 19089993.
171. Kayahara M, Wang X, Tournier C. Selective regulation of c-jun gene expression by mitogen-activated protein kinases via the 12-o-tetradecanoylphorbol-13-acetate-responsive element and myocyte enhancer factor 2 binding sites. Mol Cell Biol 2005, 25:3784-3792. 1084315, 15831482, 10.1128/MCB.25.9.3784-3792.2005.
172. Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signalling pathway to the nucleus. J Biol Chem 1999, 274:26563-26571. 10.1074/jbc.274.37.26563, 10473620.
173. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD. BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 1997, 16:7054-7066. 1170308, 9384584, 10.1093/emboj/16.23.7054.
174. English JM, Pearson G, Baer R, Cobb MH. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem 1998, 273:3854-3860. 10.1074/jbc.273.7.3854, 9461566.
175. Hayashi M, Tapping RI, Chao TH, Lo JF, King CC, Yang Y, Lee JD. BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem 2001, 276:8631-8634. 10.1074/jbc.C000838200, 11254654.
176. Leong ML, Maiyar AC, Kim B, O'Keeffe BA, Firestone GL. Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem 2003, 278:5871-5882. 10.1074/jbc.M211649200, 12488318.
177. Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 2009, 4:e5565. 2678256, 19440538, 10.1371/journal.pone.0005565.
178. Esparís-Ogando A, Díaz-Rodríguez E, Montero JC, Yuste L, Crespo P, Pandiella A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 2002, 22:270-285. 134212, 11739740, 10.1128/MCB.22.1.270-285.2002.
179. Li N, Zhang Y, Naylor MJ, Schatzmann F, Maurer F, Wintermantel T, Schuetz G, Mueller U, Streuli CH, Hynes NE. Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J 2005, 24:1942-1953. 1142608, 15889143, 10.1038/sj.emboj.7600674.
180. Xia Y, Karin M. The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol 2004, 14:94-101. 10.1016/j.tcb.2003.12.005, 15102441.
181. Suzanne M, Perrimon N, Noselli S. The Drosophila JNK pathway controls the morphogenesis of the egg dorsal appendages and micropyle. Dev Biol 2001, 237:282-294. 10.1006/dbio.2001.0384, 11543614.
182. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008, 19:1379-1386. 10.1093/annonc/mdn291, 18487549.